US20080207912A1 - Method for manufacture of ceftiofur - Google Patents
Method for manufacture of ceftiofur Download PDFInfo
- Publication number
- US20080207912A1 US20080207912A1 US12/150,744 US15074408A US2008207912A1 US 20080207912 A1 US20080207912 A1 US 20080207912A1 US 15074408 A US15074408 A US 15074408A US 2008207912 A1 US2008207912 A1 US 2008207912A1
- Authority
- US
- United States
- Prior art keywords
- ceftiofur
- water
- formula
- impurities
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 title claims abstract description 95
- 229960005229 ceftiofur Drugs 0.000 title claims abstract description 91
- 238000000034 method Methods 0.000 title claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 title description 11
- 239000012535 impurity Substances 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 37
- 239000003960 organic solvent Substances 0.000 claims abstract description 31
- 150000007530 organic bases Chemical class 0.000 claims abstract description 9
- RFLHUYUQCKHUKS-JUODUXDSSA-M Ceftiofur sodium Chemical compound [Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 RFLHUYUQCKHUKS-JUODUXDSSA-M 0.000 claims description 4
- 229960004467 ceftiofur sodium Drugs 0.000 claims description 4
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 claims 1
- 239000002585 base Substances 0.000 abstract description 17
- ZMPDMYFTSINIIZ-QHDYGNBISA-N (6r)-7-amino-3-(furan-2-carbonylsulfanylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1C(C(N1C=1C(O)=O)=O)N)CC=1CSC(=O)C1=CC=CO1 ZMPDMYFTSINIIZ-QHDYGNBISA-N 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 16
- 150000003839 salts Chemical class 0.000 abstract description 14
- 239000011541 reaction mixture Substances 0.000 abstract description 11
- 239000008346 aqueous phase Substances 0.000 abstract description 8
- 239000012074 organic phase Substances 0.000 abstract description 7
- 239000003513 alkali Substances 0.000 abstract description 5
- 239000007864 aqueous solution Substances 0.000 abstract description 5
- 239000006184 cosolvent Substances 0.000 abstract description 4
- 238000001704 evaporation Methods 0.000 abstract description 3
- 230000008020 evaporation Effects 0.000 abstract description 3
- 229920006395 saturated elastomer Polymers 0.000 abstract description 3
- 238000000638 solvent extraction Methods 0.000 abstract description 3
- 238000005192 partition Methods 0.000 abstract description 2
- 238000001556 precipitation Methods 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 description 49
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 45
- 230000015572 biosynthetic process Effects 0.000 description 33
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
- -1 acetamido cephalosporanic acid Chemical compound 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- 239000002904 solvent Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- 239000010410 layer Substances 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 239000012044 organic layer Substances 0.000 description 12
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229960004261 cefotaxime Drugs 0.000 description 8
- 229960004755 ceftriaxone Drugs 0.000 description 8
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 8
- 229940086542 triethylamine Drugs 0.000 description 8
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 7
- 229930186147 Cephalosporin Natural products 0.000 description 7
- 229940124587 cephalosporin Drugs 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 235000011007 phosphoric acid Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- MIHIJWOEDDPOLG-DUXPYHPUSA-N (2e)-2-methoxyiminoacetic acid Chemical compound CO\N=C\C(O)=O MIHIJWOEDDPOLG-DUXPYHPUSA-N 0.000 description 5
- 125000005210 alkyl ammonium group Chemical group 0.000 description 5
- 230000002051 biphasic effect Effects 0.000 description 5
- YGBFLZPYDUKSPT-MRVPVSSYSA-N cephalosporanic acid Chemical class S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)C[C@H]21 YGBFLZPYDUKSPT-MRVPVSSYSA-N 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 150000004820 halides Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 0 *C1=NN=C(S)O1.*C1=NN=C(SC(=O)/C(=N\C)C2=CSC(N)=N2)O1.C/N=C(\C(=O)O)C1=CSC(N)=N1.C=CC.CC.CC.O=C1OCCN1P(=O)(Cl)N1CCOC1=O.[2*]NC1C(=O)C2C(C)=C([4*])CSC12.[4*]C1=C(C)C2C(=O)C(NC(=O)/C(=N\C)C3=CSC(N)=N3)C2SC1 Chemical compound *C1=NN=C(S)O1.*C1=NN=C(SC(=O)/C(=N\C)C2=CSC(N)=N2)O1.C/N=C(\C(=O)O)C1=CSC(N)=N1.C=CC.CC.CC.O=C1OCCN1P(=O)(Cl)N1CCOC1=O.[2*]NC1C(=O)C2C(C)=C([4*])CSC12.[4*]C1=C(C)C2C(=O)C(NC(=O)/C(=N\C)C3=CSC(N)=N3)C2SC1 0.000 description 4
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 4
- FOHWXVBZGSVUGO-UHFFFAOYSA-N 5-phenyl-3h-1,3,4-oxadiazole-2-thione Chemical compound O1C(S)=NN=C1C1=CC=CC=C1 FOHWXVBZGSVUGO-UHFFFAOYSA-N 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 239000012455 biphasic mixture Substances 0.000 description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N butyl acetate Chemical compound CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 4
- 229960002129 cefixime Drugs 0.000 description 4
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
- KMSJGSGYXZMCEW-UHFFFAOYSA-N 1,3-benzothiazol-2-yl 2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetate Chemical compound N=1C2=CC=CC=C2SC=1OC(=O)C(=NOC)C1=CSC(N)=N1 KMSJGSGYXZMCEW-UHFFFAOYSA-N 0.000 description 3
- NLARCUDOUOQRPB-UHFFFAOYSA-N 2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetic acid Chemical compound CON=C(C(O)=O)C1=CSC(N)=N1 NLARCUDOUOQRPB-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- VYSRZETUSAOIMP-UHFFFAOYSA-N 2-furanacetic acid Chemical compound OC(=O)CC1=CC=CO1 VYSRZETUSAOIMP-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- XWHWGHSDQBXKAK-YCQCXTNNSA-N [H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 Chemical compound [H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 XWHWGHSDQBXKAK-YCQCXTNNSA-N 0.000 description 3
- 150000001242 acetic acid derivatives Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 150000002825 nitriles Chemical group 0.000 description 3
- WRTVTCFELAEIEQ-YVLHZVERSA-N o-(1,3-benzothiazol-2-yl) (2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoethanethioate Chemical compound N=1C2=CC=CC=C2SC=1OC(=S)\C(=N/OC)C1=CSC(N)=N1 WRTVTCFELAEIEQ-YVLHZVERSA-N 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000012429 reaction media Substances 0.000 description 3
- 238000009877 rendering Methods 0.000 description 3
- 229910052938 sodium sulfate Inorganic materials 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- COFDRZLHVALCDU-YVLHZVERSA-N CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1 Chemical compound CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1 COFDRZLHVALCDU-YVLHZVERSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229960000484 ceftazidime Drugs 0.000 description 2
- ORFOPKXBNMVMKC-DWVKKRMSSA-N ceftazidime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-N 0.000 description 2
- 229960001991 ceftizoxime Drugs 0.000 description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 2
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 description 2
- 229950000807 cefuzonam Drugs 0.000 description 2
- 150000001782 cephems Chemical class 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000013213 extrapolation Methods 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 2
- 239000003880 polar aprotic solvent Substances 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000001117 sulphuric acid Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- 125000005208 trialkylammonium group Chemical group 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- YTUNICCSPPTMJY-URYLQHRCSA-N (6r)-7-amino-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound CN1NC(=O)C(=O)N=C1SCC1=C(C(O)=O)N2C(=O)C(N)[C@H]2SC1 YTUNICCSPPTMJY-URYLQHRCSA-N 0.000 description 1
- GQLGFBRMCCVQLU-XCGJVMPOSA-N (6r)-7-amino-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1CC(C=C)=C(C(O)=O)N2C(=O)C(N)[C@H]21 GQLGFBRMCCVQLU-XCGJVMPOSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- PKPGSMOHYWOGJR-UHFFFAOYSA-N 2-methoxyimino-2-[2-(tritylamino)-1,3-thiazol-4-yl]acetic acid Chemical compound CON=C(C(O)=O)C1=CSC(NC(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)=N1 PKPGSMOHYWOGJR-UHFFFAOYSA-N 0.000 description 1
- RGUIGXFOHAOFLG-UHFFFAOYSA-N 2-n,3-n-dimethylpyridine-2,3-diamine Chemical compound CNC1=CC=CN=C1NC RGUIGXFOHAOFLG-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- HSHGZXNAXBPPDL-HZGVNTEJSA-N 7beta-aminocephalosporanic acid Chemical compound S1CC(COC(=O)C)=C(C([O-])=O)N2C(=O)[C@@H]([NH3+])[C@@H]12 HSHGZXNAXBPPDL-HZGVNTEJSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZMINXLRRNFPEKN-ASOPWFMASA-N C1=CC2=C(C=C1)SC(SSC1=NC3=C(C=CC=C3)S1)=N2.CO/N=C(\C(=O)O)C1=CSC(N)=N1.CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1.II Chemical compound C1=CC2=C(C=C1)SC(SSC1=NC3=C(C=CC=C3)S1)=N2.CO/N=C(\C(=O)O)C1=CSC(N)=N1.CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1.II ZMINXLRRNFPEKN-ASOPWFMASA-N 0.000 description 1
- GIVVDKIMYUIHCF-QEVHJCQDSA-N CCC(=O)/C(=N/OC)C(C)=O.I.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N/OC)C(=O)CC.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O[Si](C)(C)C)C1C(=O)[C@@]2([H])N[Si](C)(C)C Chemical compound CCC(=O)/C(=N/OC)C(C)=O.I.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N/OC)C(=O)CC.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O[Si](C)(C)C)C1C(=O)[C@@]2([H])N[Si](C)(C)C GIVVDKIMYUIHCF-QEVHJCQDSA-N 0.000 description 1
- GGZBRBJVDZKRQA-FKBXEPMKSA-N CO/N=C(\C(=O)O)C1=CSC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)=N1.I.O=C(S)C1=CC=CO1.O=C(S)C1=CC=CO1.[H][C@]12SCC(COC(C)=O)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(COC(C)=O)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 Chemical compound CO/N=C(\C(=O)O)C1=CSC(NC(C2=CC=CC=C2)(C2=CC=CC=C2)C2=CC=CC=C2)=N1.I.O=C(S)C1=CC=CO1.O=C(S)C1=CC=CO1.[H][C@]12SCC(COC(C)=O)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(COC(C)=O)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 GGZBRBJVDZKRQA-FKBXEPMKSA-N 0.000 description 1
- OBNSSTICUONGQK-JOCIJMBKSA-M CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1.I.II.I[IH]I.[BH2+].[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N/OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)[O-])C1C(=O)[C@@]2([H])NC(=O)/C(=N/OC)C1=CSC(N)=N1 Chemical compound CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1.I.II.I[IH]I.[BH2+].[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N/OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)[O-])C1C(=O)[C@@]2([H])NC(=O)/C(=N/OC)C1=CSC(N)=N1 OBNSSTICUONGQK-JOCIJMBKSA-M 0.000 description 1
- VUTQWOXFJJZENM-SPYNQHCZSA-N CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N Chemical compound CO/N=C(\C(=O)SC1=NC2=C(C=CC=C2)S1)C1=CSC(N)=N1.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N VUTQWOXFJJZENM-SPYNQHCZSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- GLLIPPRGASTLQN-UHFFFAOYSA-N Cl.OS(Cl)(=O)=O Chemical class Cl.OS(Cl)(=O)=O GLLIPPRGASTLQN-UHFFFAOYSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- QOIBBTKVHDKKRY-SORSIMBZSA-K I[IH]I.I[V]I.O=C(S)C1=CC=CO1.[H][C@]12SCC(COC(C)=O)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[V]I Chemical compound I[IH]I.I[V]I.O=C(S)C1=CC=CO1.[H][C@]12SCC(COC(C)=O)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O)C1C(=O)[C@@]2([H])N.[V]I QOIBBTKVHDKKRY-SORSIMBZSA-K 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- JBIXGXFWFFHXMR-UHFFFAOYSA-N NC1C(=O)C2C(C(=O)O)=C(CSC(=O)C3=CC=CO3)CSC12 Chemical compound NC1C(=O)C2C(C(=O)O)=C(CSC(=O)C3=CC=CO3)CSC12 JBIXGXFWFFHXMR-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- RKTNPKZEPLCLSF-GNERTXCBSA-N OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 Chemical compound OS([O-])(=O)=O.N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 RKTNPKZEPLCLSF-GNERTXCBSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- RPFPBECXOJYJLA-SQAGXFSXSA-N [H][C@]12SCC(CS)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 Chemical compound [H][C@]12SCC(CS)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1.[H][C@]12SCC(CSC)=C(C(=O)O)C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 RPFPBECXOJYJLA-SQAGXFSXSA-N 0.000 description 1
- ONJRRSDHGTZDOR-UZNHXZOVSA-M [H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O[Na])C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 Chemical compound [H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)O[Na])C1C(=O)[C@@]2([H])NC(=O)/C(=N\OC)C1=CSC(N)=N1 ONJRRSDHGTZDOR-UZNHXZOVSA-M 0.000 description 1
- MBEIUBTTWXPTGV-YWTFCRFGSA-N [H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)[O-]=B)C1C(=O)[C@@]2([H])N Chemical compound [H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(C(=O)[O-]=B)C1C(=O)[C@@]2([H])N MBEIUBTTWXPTGV-YWTFCRFGSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003849 aromatic solvent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- KVNRLNFWIYMESJ-UHFFFAOYSA-N butyronitrile Chemical compound CCCC#N KVNRLNFWIYMESJ-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- HVFLCNVBZFFHBT-ZKDACBOMSA-N cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 description 1
- 229960002100 cefepime Drugs 0.000 description 1
- MQLRYUCJDNBWMV-GHXIOONMSA-N cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 description 1
- 229960004041 cefetamet Drugs 0.000 description 1
- 229960003791 cefmenoxime Drugs 0.000 description 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N cefmenoxime Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 description 1
- 229960002838 cefpirome sulfate Drugs 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960000479 ceftriaxone sodium Drugs 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
- 238000010960 commercial process Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- TVMUHOAONWHJBV-UHFFFAOYSA-N dehydroglycine Chemical compound OC(=O)C=N TVMUHOAONWHJBV-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- FDRNWTJTHBSPMW-GNXCPKRQSA-L disodium;(6r,7r)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-6-oxido-5-oxo-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C FDRNWTJTHBSPMW-GNXCPKRQSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940024448 excenel Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 229940017578 naxcel Drugs 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- MOLSHLPWPPSZQG-UHFFFAOYSA-N sulfino acetate Chemical compound CC(=O)OS(O)=O MOLSHLPWPPSZQG-UHFFFAOYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to an improved method for manufacture of Ceftiofur in high purity.
- the present invention relates to an improved method for manufacture of Ceftiofur substantially free from impurities.
- Ceftiofur is a broad-spectrum third generation antibiotic, which is primarily used for veterinary use. It is known chemically as (6R, 7R)-7-[[(2Z)-(2-amino-4-thiazolyl) (methoxyimino) acetyl]amino]-3-[[(2-furanylcarbonyl) thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid and is represented by the formula (I).
- Ceftiofur is commercially sold as the sodium salt and is marketed under the brand names Naxcel® and Excenel® for parenteral administration, in bovine animals.
- Ceftiofur has been synthesized by any of the following three methods, viz, I. Ceftiofur and its salts thereof, especially the sodium salt is described in U.S. Pat. No. 4,464,367 (Labeeuw et. al). The patent describes two methods for preparation of Ceftiofur (I) comprising,
- U.S. Pat. No. 4,464,367 contains enabling disclosure for preparation of ceftiofur as per method (1) comprising reaction of 7-amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid with the syn isomer of (2-tritylaminothiazol-4-yl)-2methoxyimino acetic acid activated with 1-hydroxy benzotriazole, followed by removal of the trityl protecting group to give ceftiofur (I).
- ceftiofur as per method-I involves additional steps of protection of the amino group of [2-(2-aminothiazol4-yl)]-2-syn methoxyimino acetic acid with trityl chloride followed by deprotection in presence of formic acid to give ceftiofur of formula (I).
- the amidification method utilises toxic, expensive dicyclohexyl carbodiimide for preparing the activated ester of [2-(2-aminothiazol-4-yl)]-2-syn methoxyimino acetic acid with 1-hydroxy benzotriazole, resulting in the formation of dicyclohexyl urea, which is difficult to remove.
- the method comprises, reaction of 4-halo-3-oxo-2-methoxyimino butyric acid, activated as the acid halide, with silylated 7-amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid to give the corresponding 7-carboxamido derivative which on subsequent treatment with thiourea gives ceftiofur of formula (I).
- the thiazole
- U.S. Pat. No. 6,388,070 (Deshpande, et. al) teaches a method for synthesis of ceftiofur (I), and other cephalosporin compounds like ceftriaxone and ceftazidime, cefixime, cefpodoxime acid, cefetamet and cefotaxime acid.
- [2-(2-aminothiazol-4-yl)]-2-syn methoxyimino acetic acid is activated as the thioester by reaction with 2-mercapto-5-phenyl-1,3,4-oxadiazole in the presence of bis-(2-oxo-oxazidinyl)phosphinic chloride.
- the thioester on reaction with silylated 7-amino-3-substituted-3-cephem compounds in the presence of a base at low temperatures gives the corresponding 7-acylamido-3-substituted-3-cephem cephalosporin, depicted in scheme-III, herein below:
- a reactive derivative of [(2)-(2-aminothiazol-4-yl)]-2-syn-oxyimino acetic acid compounds widely utilized in cephalosporin chemistry for effecting amidification at 7-position is the 2-benzothiazolyl thioester, first disclosed in U.S. Pat. No. 4,767,852 (Ascher et. al), the chemistry of which is shown hereinbelow.
- cephalosporin compounds that fall under the definition of the group R 4 of this patent include the commercially and therapeutically valuable cephalosporin antibiotics like cefotaxime, ceftriaxone and cefuzonam.
- the group R 4 of U.S. Pat. No. 4,767,852 does not encompass ceftiofur as it covers only those 3-thiomethyl compounds in which the sulphur atom is directly attached to a heterocyclic ring, and not those compounds in which a carbonyl group is interposed between S and Y, where Y is a heterocyclic ring; Ceftiofur (I) has a carbonyl group interposed between S and Y i.e. between the 3-thiomethyl group and the furan ring.
- the method comprises reacting a protected 7-amino-3-substituted cephalosporanic acid derivative, particularly a protected 7-amino-3-vinyl-3-cephem-4-carboxylic acid, wherein the amino group and the carboxylic group are protected as trialkylsilyl group with a [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl thioester in the form of a aqueous solution of a crystalline solvate with dimethyl acetamide and an inert organic solvent medium at room temperature in the presence of a base to give cefixime after removal of the said protective groups.
- Cefixime is isolated as the salt of an organic base or as an acid addition salt with sulphuric acid.
- the improvement comprises carrying out the said amidification reaction in a monophasic system comprising a mixture of a water-miscible organic solvent and water and in the presence of an organic base.
- a monophasic system comprising a mixture of a water-miscible organic solvent and water and in the presence of an organic base.
- the water-miscible organic solvents listed in the U.S. Pat. No. 5,026,843 as useful for carrying out the abovementioned synthesis include tetrahydrofuran, dimethyl acetamide, dimethyl formamide, dioxane, dimethoxyethane. When these solvents are mixed with water, a homogeneous single phase would result. This helps in keeping the ceftiaxone thus produced in solution throughout the reaction and thereby, enabling a one-pot reaction for preparation of ceftriaxone sodium.
- ceftiofur (I) which not only satisfies the techno-commercial aspects i. e. cost-effectiveness, ease of operations, etc, but also provides a product of high purity, free of impurities and possess properties, which are amenable for formulation into a suitable dosage form.
- An object of the invention is to provide a method for manufacture of ceftiofur of formula (I) of high purity and substantially free of impurities.
- Another object of the present invention is to provide a method for manufacture of ceftiofur of formula (I) comprising reaction of 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III) with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid activated as its -2-benzothiazolyl ester of formula (II) in a biphasic system comprising mixture of a water-immiscible inert organic solvent and water and in the presence of base, wherein the formation of impurities is substantially minimized with concomitant higher conversion to the desired product.
- Yet another object of the present invention is to provide a selective method for isolation of ceftiofur of formula (I), providing the product in high yield and high purity and substantially free of impurities.
- the present invention provides a simple, cost-effective method for manufacture of ceftiofur of formula (I),
- ceftiofur of formula (I), in high purity and substantially free of impurities in the presence of a mixture comprising a water-immiscible inert organic solvent, and water and in the presence of a base and isolation to give ceftiofur of formula (I), in high purity and substantially free of impurities.
- the present invention provides a method for isolation of ceftiofur of formula (I), in high purity and substantially free of impurities comprising,
- 7-Amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid of formula (III) can be prepared by the method disclosed in U.S. Pat. No. 4,937,330, comprising reaction of thiofuroic acid of formula (VI) with 7-amino cephalosporanic acid of formula (VII) at pH 6.4 and temperature of 65° C. in a mixture of water and an inert solvent such as ethyl acetate.
- [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester (MAEM) (II) can be prepared by the method described in EP Patent No. 0,037,380 comprising reaction of [2-(2-aminothiazol-4-yl)-2-syn-methoxyimino] acetic acid (IX) with bis[benzthiazolyl-(2)] disulphide (X) in the presence of triphenyl phosphine and dichloromethane as solvent at 0° C.
- an inert water-immiscible organic solvent is one, which does not participate in the reaction but helps facilitate smooth conversion of the reactants into the end product i. e. ceftiofur.
- Typical of such water-immiscible inert organic solvents that can be employed are selected from chlorinated hydrocarbons such as dichloromethane, dichloroethane, chloroform etc
- any polar solvent say a C 1-4 alkanol
- water for conducting the reaction in admixture with the water-immiscible inert organic solvent, resulting in a homogeneous phase
- polar solvents do not contribute in reducing the formation of impurities.
- Water when employed in admixture with a water-immiscible inert organic solvent ensures a heterogenous biphasic system, which substantially helps minimization of the impurities.
- the ratio of the water-immiscible inert organic solvent to water can vary from 90:10 of the former to the latter to 98:2.0 of the same, the best results are obtained when the ratio is between 95:5.0 to 97.5:2.5 of the water-immiscible inert organic solvent to water.
- the reaction can be carried out a temperature ranging between low to ambient i. e. from 0° C. to 30° C., but preferably at a temperature ranging between 0° C. to 15° C.
- any base can be used, organic bases are preferred. Typical of such bases that can be employed include triethylamine, tri-n-butylamine, tert-butylamine, dicyclohexylanine, N-methyl morpholine, 2,3-dimethylaminopyridine, N-methyl pyrrolidinone etc.
- tertiary amines are preferred which are selected from triethyl amine, tri-n-propyl amine, tri-n-butyl amine. Triethyl amine is preferred among the tertiary amines as impurity formation is minimized.
- the rise in impurity formation by using organic bases having higher number of carbon atoms may be presumably due to the increase in the hydrophobicity of the trialkyl ammonium salt (III 2 ) with the increase in the number of carbon atoms in the trialkyl amine.
- This increase in hydrophobicity leads to increase in the solubility of the trialkyl ammonium salt (III 2 ) in the hydrophobic solvent due to which the acylation takes place in the hydrophobic solvent and not at the interphase between the aqueous phase and the hydrophobic phase resulting in a rise in the level of impurities.
- the base can be employed in molar proportions of 1.0 mole to 3.0 moles per mole of compound of formula (III).
- the base is employed in molar proportions of 1.0 moles to 2.0 moles per mole of the compound of formula (III).
- [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II) is employed in molar proportions of 1.0 to 2.0 moles per mole of the compound of formula (III), but preferably in a molar proportion of 1.0-1.5 moles.
- the progress of the reaction can be monitored by TLC or HPLC and typically depending upon the temperature employed the reaction is over in a period ranging from 1.0 to 3.0 hours, with the monitoring system indicating more than 95% conversion to ceftiofur (I).
- aqueous layer is separated and further washed with a water-immiscible organic solvent selected from a chlorinated solvent such as dichloromethane, dichloroethane, chloroform or C 1-6 alkyl acetate like ethyl acetate, propyl acetate, n-butyl acetate at least once.
- a chlorinated solvent such as dichloromethane, dichloroethane, chloroform or C 1-6 alkyl acetate like ethyl acetate, propyl acetate, n-butyl acetate at least once.
- aqueous layer To the aqueous layer is added a mixture of a water-miscible solvent and a water-immiscible solvent, after separation of the organic layer.
- the water-miscible organic solvent is selected from nitriles such as acetonitrile, propionitrile, butyronitrile or ketones such as acetone, methyl ethyl ketone or polar aprotic solvents like dimethyl sulphoxide, sulpholane.
- the preferred water-miscible solvent is a nitrile, preferably acetonitrile.
- the water-immiscible solvent is selected from chlorinated solvents like dichloromethane, dichloroethane, chloroform or C 1-6 alkyl acetates like ethyl acetate, n-butyl acetate, isopropyl acetate but preferably ethyl acetate.
- a mixture of alkyl acetate preferably ethyl acetate and nitrile preferably acetonitrile is added to the aqueous layer containing the alkyl ammonium salt of ceftiofur (I).
- the ratio of the mixture of water-miscible solvent and water-immiscible solvent is between (1:1) and (5:1) but preferably the ratio of alkyl acetate and the polar aprotic solvent is (2:1 or 3:1).
- the pH of the mixture is adjusted to 3.0 ⁇ 0.1 by addition of orthophosphoric acid and the mixture agitated further for complete liberating the ceftiofur (I) free acid from its corresponding salt with a organic base and taking it to the organic phase.
- a mineral acid selected from hydrochloric acid, sulphuric acid, orthophosphoric acid but preferably orthophosphoric acid is added to the biphasic mixture.
- a saturated solution of an alkali or an alkaline earth metal containing salt (15-30%) is added to the biphasic system and agitated at ambient temperature.
- the organic layer is separated and the aqueous layer is optionally again extracted with a mixture of water-miscible solvent and a water-immiscible solvent.
- the alkali or an alkaline earth metal containing salt is selected from sodium chloride, sodium sulphate, potassium chloride, potassium sulphate, calcium chloride, but preferably sodium chloride.
- Ceftiofur of formula (I) is isolated from the organic layer by evaporation of the organic solvent or by addition of a co-solvent.
- the co-solvent added for precipitating out ceftiofur (I) at ambient temperature from the organic layer can be a non-polar aromatic solvent like toluene, xylene or aliphatic solvent like cyclohexane, n-hexane, heptane.
- ceftiofur (I) The mixture is agitated between 45-90 minutes but preferably 60 minutes for complete crystallization of pure ceftiofur (I).
- the pure compound (I) is filtered, washed with cyclohexane and dried at 35-40° C.
- the purity of ceftiofur (I) thus obtained has purity above 97% and substantially free from impurities such as the dimer compound (IV) and thiol compound (V).
- Ceftiofur acid of formula (I) thus prepared exhibits remarkable stability under stringent temperature and humidity conditions of 40 ⁇ 2° C. and relative humidity of 75% ⁇ 5° C. even after 3 months of storage.
- a (2:1) mixture of ethyl acetate and acetonitrile is added to the aqueous layer and agitated at ambient temperature.
- the pH of the mixture is adjusted to 3.0 ⁇ 0.1 with orthophosphoric acid (30%) at ambient temperature.
- a 20% aqueous solution of sodium chloride is added to the biphasic mixture and agitated.
- the organic layer is separated and after optional treatment with activated carbon followed by filtration through celite bed is concentrated to isolate ceftiofur of formula (I).
- cyclohexane is added to the organic layer and ceftiofur of formula (I) is allowed to precipitate completely at ambient temperature.
- the mixture is filtered and the wet cake washed with cyclohexane followed by drying at 35-40° C. to give ceftiofur (I) substantially free from impurities and with purity greater than 97%.
- Stability Stable for 3 months at Impurity level is quite Starts degrading in the — — of 40 ⁇ 2° C. and relative high, therefore, stability first month at 40 ⁇ 2° C. ceftiofur humidity 75% ⁇ 5 is low. and relative humidity sodium 75% ⁇ 5; purity falls prepared below specified limits in from the the first month itself.
- Ceftiofur sodium can be prepared from ceftiofur acid (I) by methods disclosed in the prior art. Ceftiofur acid (I) prepared by the present method has been converted to its sodium salt by a method disclosed in a co-pending application No. 938/MUM/2002 dated Oct. 29, 2002.
- Ceftiofur sodium prepared from ceftiofur acid (I) made by the present method has higher stability due to the lower level of impurities generated during the preparation of ceftiofur acid (I) and is also amenable to formulation as a dosage form.
- the pH was adjusted to 3.0 by adding 25% orthophosphoric acid in 30 minutes at 15-20° C.
- a concentrated solution of sodium chloride (25%) was added to the biphasic mixture and the resulting biphasic mixture was agitated for 30 minutes.
- the organic layer was separated and the aqueous layer re-extracted with a (2:1) mixture of ethyl acetate and acetonitrile (750 ml).
- the organic layers were combined and washed with 5% brine solution.
- the organic layer was separated and after optional carbon treatment followed by filtration was dried on sodium sulphate.
- the reaction mixture was monitored by HPLC and stirred for 3.0 hours at 5 ⁇ 2° C.; the reaction was not going to completion as 2.5% was remaining unreacted even after stirring further for 2.0 hours.
- the reaction mixture was quenched with water.
- the aqueous layer was washed with dichloromethane (45 ml) at least once followed by washing with ethyl acetate (45 ml).
- Ethyl acetate (15 m) was added to the aqueous layer and the pH was adjusted to pH 3 with 30% orthophosphoric acid.
- the organic layer was separated dried on sodium sulphate and evaporated between 25-30° C. under reduced pressure.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
Abstract
A process for preparation of ceftiofur of formula (I) of high purity and substantially free from impurities is disclosed. The process comprises reacting [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II), with 7-amino-3-(2-furanylcarbonylthiomethyl)-3-cephem-4-carboxylic acid of formula (III) in the presence of a mixture of an water-immescible inert organic solvent and water and in the presence of a organic base and isolating ceftiofur of formula (1) substantially free of impurities by, d) adding water to the reaction mixture and selectively partitioning the impurities in the organic phase and ceftiofur (I) in the form of a salt with the base in the aqueous phase, e) acidifying the aqueous phase containing ceftiofur (I) in the form of a salt with the base in the presence of a mixture containing a water-miscible and a water-immiscible organic solvent and in the presence of a saturated aqueous solution of an alkali or alkaline earth containing salt, to partition ceftiofur (I) in the organic phase, and f) isolating ceftiofur (I) of high purity and substantially free of impurities by evaporation of the organic solvent or precipitation by addition of a co-solvent.
Description
- The present invention relates to an improved method for manufacture of Ceftiofur in high purity. In particular, the present invention relates to an improved method for manufacture of Ceftiofur substantially free from impurities.
- Ceftiofur is a broad-spectrum third generation antibiotic, which is primarily used for veterinary use. It is known chemically as (6R, 7R)-7-[[(2Z)-(2-amino-4-thiazolyl) (methoxyimino) acetyl]amino]-3-[[(2-furanylcarbonyl) thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid and is represented by the formula (I).
- Ceftiofur is commercially sold as the sodium salt and is marketed under the brand names Naxcel® and Excenel® for parenteral administration, in bovine animals.
- Ceftiofur has been synthesized by any of the following three methods, viz, I. Ceftiofur and its salts thereof, especially the sodium salt is described in U.S. Pat. No. 4,464,367 (Labeeuw et. al). The patent describes two methods for preparation of Ceftiofur (I) comprising,
- i) amidification at the 7-position of 7-amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid with a suitably activated [(2Z)-(2-tritylamino-4-thiazolyl) methoxyimino] acetic acid derivative such as mixed anhydride or an activated ester to give ceftiofur (I) after necessary deprotection.
- ii) functionalisation at the 3-position of a 7-[2-(2-aminothiazol-4-yl)-2-syn-methoxyimino] acetamido cephalosporanic acid i.e. cefotaxime acid, with thiofuroic acid to give Ceftiofur (I).
- U.S. Pat. No. 4,464,367 contains enabling disclosure for preparation of ceftiofur as per method (1) comprising reaction of 7-amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid with the syn isomer of (2-tritylaminothiazol-4-yl)-2methoxyimino acetic acid activated with 1-hydroxy benzotriazole, followed by removal of the trityl protecting group to give ceftiofur (I).
- However, for method (II), apart from the reaction sequence given in column 3, lines 25-35 depicting conversion of cefotaxime to ceftiofur (I), there is no enabling disclosure whatsoever about how the conversion could be carried out.
- The two methods for preparation of ceftiofur of formula (I) are summarized in scheme (I).
- Further, synthesis of ceftiofur as per method-I involves additional steps of protection of the amino group of [2-(2-aminothiazol4-yl)]-2-syn methoxyimino acetic acid with trityl chloride followed by deprotection in presence of formic acid to give ceftiofur of formula (I). The amidification method utilises toxic, expensive dicyclohexyl carbodiimide for preparing the activated ester of [2-(2-aminothiazol-4-yl)]-2-syn methoxyimino acetic acid with 1-hydroxy benzotriazole, resulting in the formation of dicyclohexyl urea, which is difficult to remove.
- II. Although) the claims of U.S. Pat. No. 6,458,949 B1 (Handa, et al) appear to be obvious, over prior art described in EP Patent No. 0,302,94, U.S. Pat. No. 5,109,135, and U.S. Pat. No. 5,109,131 the said patent however discloses another method for the preparation of Ceftiofur (I), which is summarized in scheme-II.
- The method comprises, reaction of 4-halo-3-oxo-2-methoxyimino butyric acid, activated as the acid halide, with silylated 7-amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid to give the corresponding 7-carboxamido derivative which on subsequent treatment with thiourea gives ceftiofur of formula (I). Herein, the thiazole
- The method described in U.S. Pat. No. 6,458,949 B1 is complicated and tedious, as it involves initial preparation of 4-halo-3-oxo-2-methoxyimino butyric acid requiring four steps followed by subsequent amidification reaction with 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid and cyclisation with thiourea. The overall yield of (I) is therefore low, rendering the method commercially not very attractive.
- III. U.S. Pat. No. 6,388,070 (Deshpande, et. al) teaches a method for synthesis of ceftiofur (I), and other cephalosporin compounds like ceftriaxone and ceftazidime, cefixime, cefpodoxime acid, cefetamet and cefotaxime acid.
- Herein, [2-(2-aminothiazol-4-yl)]-2-syn methoxyimino acetic acid is activated as the thioester by reaction with 2-mercapto-5-phenyl-1,3,4-oxadiazole in the presence of bis-(2-oxo-oxazidinyl)phosphinic chloride. The thioester on reaction with silylated 7-amino-3-substituted-3-cephem compounds in the presence of a base at low temperatures gives the corresponding 7-acylamido-3-substituted-3-cephem cephalosporin, depicted in scheme-III, herein below:
- The activation of [2-(2-aminothiazol-4-yl)]-2-syn methoxyimino acetic acid with 2-mercapto-5-phenyl-1,3,4-oxadiazole is quite slow and it requires a time upto 34 hours. Moreover, the method utilizes a reagent like bis-(2-oxo-oxazidinyl) phosphinic chloride which is expensive.
- Apart from the above methods, which utilize activation of the carboxylic acid moiety of either the [2-(2-aminothiazol-4-yl)]-2-syn methoxyimino acetic acid or 4-halo-3-oxo-2-methoxyimino butyric acid through the formation of a mixed anhydride or activated ester with 1-hydroxy benzotriazole or 2-mercapto-5-phenyl-1,3,4-oxadiazole or an acid chloride, there are no reports of synthesis of ceftiofur (I) by other methods, specially through utilization of other reactive derivatives of the said carboxylic compounds.
- Various reactive derivatives of [2-(2-aminothiazol-4-yl)]-2-oxyimino acetic acid compounds have been utilized for synthesis of several 3-substituted cephalosporin antibiotics carrying a [2-(2-aminothiazol-4-yl)]-2-oxyimino acetamido addendum in the 7-position. These include, to a name a few
- a) an acyloxyphosphonium halide derivative as disclosed in U.S. Pat. No. 5,317,099 (Lee et. al) for synthesis of cefotaxime and cefriaxone;
- b) an acetyl sulfite dialkyl formiminium halide hydrohalide derivative as disclosed in U.S. Pat. No. 5,037,988 (Meseguer et. al) for synthesis of cefotaxime, ceftriaxone, cefmenoxime, ceftizoxime, and ceflazidime;
- c) a dialkyl chloro thiophosphate ester as disclosed in U.S. Pat. No 5,567,813 (Sung et. al) for synthesis of cefotaxime, ceftriaxone, cefemenoxime, ceftizoxime, cefpirome sulfate and cefepime;
- d) a dimethyl forminium chloride chlorosulphate derivative as disclosed in U.S. Pat. No. 5,739,346 (Datta et. al) for synthesis of cefotaxime, ceftriaxone, ceftazidime, cefazolin etc.
- A reactive derivative of [(2)-(2-aminothiazol-4-yl)]-2-syn-oxyimino acetic acid compounds widely utilized in cephalosporin chemistry for effecting amidification at 7-position is the 2-benzothiazolyl thioester, first disclosed in U.S. Pat. No. 4,767,852 (Ascher et. al), the chemistry of which is shown hereinbelow.
- wherein the groups R1 to R3 are as defined therein and the group R4 is an acetoxy, carbamoyloxy, or is a group of formula S—Y, wherein Y is a heterocyclic ring.
- The cephalosporin compounds that fall under the definition of the group R4 of this patent include the commercially and therapeutically valuable cephalosporin antibiotics like cefotaxime, ceftriaxone and cefuzonam.
- The group R4 of U.S. Pat. No. 4,767,852 does not encompass ceftiofur as it covers only those 3-thiomethyl compounds in which the sulphur atom is directly attached to a heterocyclic ring, and not those compounds in which a carbonyl group is interposed between S and Y, where Y is a heterocyclic ring; Ceftiofur (I) has a carbonyl group interposed between S and Y i.e. between the 3-thiomethyl group and the furan ring.
- The method disclosed in U.S. Pat. No. 4,767,852, as is evident from description given in the examples of the said patent, essentially consists reaction of a protected 7-amino-3-substituted cephalosporanic acid derivative, in particular a (N,O)-bis silylated 7-amino-3-substituted cephalosporanic acid derivative with the [2-(2-aminothiazol-4-yl)]-2-syn-oxyimino acetic acid-2-benzothiazolyl thioester in an inert organic solvent at ambient temperature for a time ranging between 0.5 to 48.0 hours to give the object [2-(2-aminothiazol-4-yl)]-2-syn-oxyimino acetamido-3-substituted-3-cephem-4-carboxylic acid compounds such as cefotaxime, ceftriaxone and cefuzonam, which it should be noted carries “a residue of a nucleophile at the 3α-position”.
- From the abovementioned methods it is apparent that the preparation of the [2-(2-aminothiazol-4-yl)]-2-oxyimino acetamido-3-substituted-3-cephem-4-carboxylic acid compounds is effected essentially in an inert organic solvent, thereby implying a reaction medium free of water and through utilization of a protected 7-amino-3-substituted cephalosporanic acid derivative as the starting material.
- In addition, the [2-(2-aminothiazol-4-yl)]-2-oxyimino acetic acid-2-benzothiazolyl thioester has also been utilized for synthesis of other [2-(2-aminothiazol-4-yl)]-2-oxyimino acetamido-3-substituted-3-cephem-4-carboxylic acid compounds such as cefixime as disclosed in U.S. Pat. No. 6,313,289. Here again, the method comprises reacting a protected 7-amino-3-substituted cephalosporanic acid derivative, particularly a protected 7-amino-3-vinyl-3-cephem-4-carboxylic acid, wherein the amino group and the carboxylic group are protected as trialkylsilyl group with a [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl thioester in the form of a aqueous solution of a crystalline solvate with dimethyl acetamide and an inert organic solvent medium at room temperature in the presence of a base to give cefixime after removal of the said protective groups.
- Cefixime is isolated as the salt of an organic base or as an acid addition salt with sulphuric acid.
- In their attempt to extend the method described in U.S. Pat. No. 4,767,852 and U.S. Pat. No. 6,313,289, for synthesis of ceftiofur the present inventors found to their surprise that when (N,O)-bis silyl-7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III1),
- is reacted with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl thioester (MAEM) of formula (II)
- in an inert organic solvent (dichloromethane) in the presence of an organic base (triethyl amine) at ambient temperature (15-30° C.), the methods had the following disadvantages, which are undesirable for any commercial process. These are,
- i) the reaction required a period of more than 20-24 hours to proceed to completion,
- ii) the conversion to ceftiofur as indicated by monitoring of the reaction by HPLC was only about 88-90%,
- iii) about 9-10% of impurities were formed in the reaction,
- iv) the product i. e. ceftiofur was isolated as a gummy material, and
- v) the isolated product i. e. ceftiofur had a purity of only about 88% containing about 10-12% of impurites. Purification of the material thus obtained resulted in considerable loss thus giving ceftiofur (I) in low yield.
- An improved method for synthesis of ceftriaxone comprising reaction of [2-(2-aminothiazol-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (III) with a unprotected 7-amino-3-substituted cephalosporanic acid derivative i. e. 7-amino-3-(2,5-dihydro-6-hydroxy-2-methyl-5-oxo-1,2,4-triazin-3-yl)thiomethyl-3-cephem-4-carboxylic acid has been disclosed in U.S. Pat. No. 5,026,843 (Riccardo et. al.). The improvement comprises carrying out the said amidification reaction in a monophasic system comprising a mixture of a water-miscible organic solvent and water and in the presence of an organic base. The ceftriaxone thus obtained without isolation is converted into its sodium salt, which is isolated from the reaction mixture. The chemistry is summarized hereinbelow:
- The water-miscible organic solvents listed in the U.S. Pat. No. 5,026,843 as useful for carrying out the abovementioned synthesis include tetrahydrofuran, dimethyl acetamide, dimethyl formamide, dioxane, dimethoxyethane. When these solvents are mixed with water, a homogeneous single phase would result. This helps in keeping the ceftiaxone thus produced in solution throughout the reaction and thereby, enabling a one-pot reaction for preparation of ceftriaxone sodium.
- An attempt by the present inventors to extend the method described in U.S. Pat. No. 5,026,843 for synthesis of ceftiofur or ceftiofur sodium comprising reaction of [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl thioester (MAEM) of formula (II) with 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III),
- in a medium consisting of water and a water-miscible organic solvent disclosed in the said patent like tetrahydrofuran and N,N-dimethylacetamide, was however, not satisfactory and was found to give the product i. e. ceftiofur (I) associated with impurities in the level of 5-10% depending on the water-miscible organic solvent used. The product obtained was a sticky solid adhering to the sides of the reaction vessel, rendering its isolation as a solid very difficult.
- In addition, replication of the methods exactly as described in U.S. Pat. No. 4,464,367 and U.S. Pat. No. 6,458,949 B1, referred herein earlier were also found to be associated with formation of higher level of impurites, which are to the tune of about 25-28% and 5-10% respectively.
- The level of impurites formed in the synthesis of ceftiofur by the four methods discussed herein before are summarized in Table-I.
-
TABLE I The level of impurities formed in the synthesis of ceftiofur (I) by various methods % Total No. Method Conversion Impurities (%) % Yield Purity % 1 As per that described in U.S. Pat. No. 75 25-28 Gummy — 4,464,367 material (not isolated) 2 As per that described in U.S. Pat. No. 91.2 8.8 69.6 92.78 6,458,949 B1 3 Extrapolation of the method described in 89 11 Sticky — U.S. Pat. No. 4,767,852* solid (not isolated) 4 Extrapolation of the method described in 93 5-10 Sticky — U.S. Pat. No. 5,026,843** solid (not isolated) *reaction of (N,O)-bis silyl-7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III1) with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II) in dichloromethane at ambient temperature **reaction of 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (II) with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (III) in a medium containing water and a water-miscible organic solvent in presence of a base - It might be mentioned herein that the 3-thiofuroylmethyl substituent in ceftiofur, by virtue of it containing a carbonyl group interposed between a sulfur atom and a furan ring system is very labile in nature and is highly susceptible to fission of the sulfur-carbonyl bond as well as highly prone to undergo dimerisation, leading to formation of a dimeric compound in solution. This sets apart ceftiofur (I) from other 3-heterocyclic thiomethyl cephalosporin derivatives as described in U.S. Pat. No. 4,767,852 wherein the abovementioned lability is less pronounced or negligent and thereby ensuring their synthesis through any known methods.
- The structure of the impurities arising out of fission of the sulfur-carbonyl bond and dimerization are given herein below as compounds (IV) and (V) respectively.
- Thus, to summarize,
- i) Synthesis of ceftiofur (I) had been achieved in prior art either through amidification at the 7-amino position of (a suitably protected) 7-amino3-thiofuroylmethyl-3-cephalosporanic acid with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid activated through formation of a mixed anhydride or through formation of an activated ester with 1-hydroxybenzotriazole, or 2-mercapto-5-phenyl-1,3,4-oxadiazole and described respectively in U.S. Pat. No. 4, 464,367 and U.S. Pat. No. 6,388,070 B1, summarized in Scheme-I and Scheme-III, or through amidification at the 7-amino position of (a suitably protected) 4-halo-2-methoxyimino-3-oxo butyric acid activated as the acid halide, followed by cyclization of the intermediate compound thus formed with thiourea, as described in U.S. Pat. No. 6,458,949 B1 and summarized in Scheme-II;
- ii) Functionalization at 3-position of cefotaxime by reaction with thiofuroic acid, as summarized in Scheme-I, for the conversion of which, however, there is no enabling disclosure whatsoever in U.S. Pat. No. 4,464,367;
- iii) Replication of both the abovementioned methods was found to give ceftiofur associated with impurities in the range of 5-28%;
- iv) Extension of the methods described in U.S. Pat. No. 4,767,852 and U.S. Pat. No. 5,026,843 for synthesis of ceftiofur (I) was not only lengthy requiring about 18-24 hours but also lead to higher levels of impurity, resulting in a gummy material.
- v) The abovementioned methods involve protection and deprotection of reactive functional groups, increasing the cost and time of manufacture;
- vi) The product i. e. ceftiofur obtained by the abovementioned methods, because of the higher level of impurities is therefore not suitable for formulation into a suitable dosage form; and
- vii) Removal of the impurities by purification leads to considerable loss of the product, increasing the cost of manufacture and rendering such methods commercially not attractive.
- Further, since regulatory authorities all over the world are highly concerned about the level of impurities in a drug substance/drug product and are becoming increasingly stringent in approving products containing levels of impurities above the prescribed limits for human or animal consumption, it is imperative that any method of manufacture of a drug substance/drug product, apart from being commercially viable should provide the product conforming to pharmacopoeial specifications, containing amount of impurities within the prescribed limits or subatantially free of such impurities.
- In view of the foregoing reasons, there exists a need for a vastly improved method for manufacture of ceftiofur (I), which not only satisfies the techno-commercial aspects i. e. cost-effectiveness, ease of operations, etc, but also provides a product of high purity, free of impurities and possess properties, which are amenable for formulation into a suitable dosage form.
- The present inventors have found to their surprise that the existing need for an improved method for manufacture of ceftiofur in high yield and high purity could be achieved through:
- i) carrying out amidifaction at 7-amino position of 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III) with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid activated as its -2-benzothiazolyl ester of formula (II), obviating the need for protection and deprotection of reactive functional groups,
- ii) the said amidification reaction is carried out in a system comprising mixture of a water-immiscible inert organic solvent and water i.e. a biphasic system and in the presence of a base, in a remarkably shorter time (1.5 to 3.0 hours) resulting in a product with substantially lower level of impurities,
- iii) removal of most of the impurities formed during the above reaction in (ii) above, through a selective extraction method to provide ceftiofur (I) of high purity and substantially free of impurities by extraction of the aqueous mixture of the alkyl ammonium salt of ceftiofur (I) with a inert organic solvent.
- iv) further removal of impurities formed during acidification of the alkyl ammonium salt of ceftiofur (I) with a mineral acid, in the presence of a mixture of water-miscible and water-immiscible solvent and in the presence of a saturated aqueous solution of an alkali or alkaline earth containing salt, by selectively partitioning ceftiofur (I) in the organic phase substantially free from impurities with the associated impurities getting extracted in the aqueous phase.
- An object of the invention is to provide a method for manufacture of ceftiofur of formula (I) of high purity and substantially free of impurities.
- Another object of the present invention is to provide a method for manufacture of ceftiofur of formula (I) comprising reaction of 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III) with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid activated as its -2-benzothiazolyl ester of formula (II) in a biphasic system comprising mixture of a water-immiscible inert organic solvent and water and in the presence of base, wherein the formation of impurities is substantially minimized with concomitant higher conversion to the desired product.
- Yet another object of the present invention is to provide a selective method for isolation of ceftiofur of formula (I), providing the product in high yield and high purity and substantially free of impurities.
- In one aspect, the present invention provides a simple, cost-effective method for manufacture of ceftiofur of formula (I),
- comprising reaction of [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl ester of formula (II), and
- 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III),
- in the presence of a mixture comprising a water-immiscible inert organic solvent, and water and in the presence of a base and isolation to give ceftiofur of formula (I), in high purity and substantially free of impurities.
- In another aspect, the present invention provides a method for isolation of ceftiofur of formula (I), in high purity and substantially free of impurities comprising,
- i) addition of water to the reaction mixture and selective partitioning of the impurities in the organic phase and ceftiofur (I) in the form of a salt with the base in the aqueous phase,
- ii) acidification of the aqueous phase containing ceftiofur (I) in the form of a salt with the base in the presence of a mixture containing a water-miscible and a water-immiscible organic solvent and in the presence of a saturated aqueous solution of au alkali or alkaline earth containing salt, to partition ceftiofur (I) in the organic phase, and iii) isolation of ceftiofur (I) of high purity and substantially free of impurities by evaporation of the organic solvent or precipitation by addition of a co-solvent.
- The method for preparation of ceftiofur (I) as per the present invention is summarized in Scheme-V for ready reference,
- The starting materials required are prepared by known methods. 7-Amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid of formula (III) can be prepared by the method disclosed in U.S. Pat. No. 4,937,330, comprising reaction of thiofuroic acid of formula (VI) with 7-amino cephalosporanic acid of formula (VII) at pH 6.4 and temperature of 65° C. in a mixture of water and an inert solvent such as ethyl acetate.
- [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester (MAEM) (II) can be prepared by the method described in EP Patent No. 0,037,380 comprising reaction of [2-(2-aminothiazol-4-yl)-2-syn-methoxyimino] acetic acid (IX) with bis[benzthiazolyl-(2)] disulphide (X) in the presence of triphenyl phosphine and dichloromethane as solvent at 0° C. The product (II) separating out is filtered, washed with dichloromethane followed by stirring with ethyl acetate at 0° C. and filtration to give [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II).
- In a typical method for preparation of ceftiofur of formula (I), 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III) is added to a mixture of the water-immiscible inert organic solvent and water, followed by addition of the base. To the mixture is added [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl ester of formula (II) and the reaction mixture agitated till completion of reaction to give ceftiofur of formula (I).
- By definition an inert water-immiscible organic solvent is one, which does not participate in the reaction but helps facilitate smooth conversion of the reactants into the end product i. e. ceftiofur.
- Typical of such water-immiscible inert organic solvents that can be employed are selected from chlorinated hydrocarbons such as dichloromethane, dichloroethane, chloroform etc
- While, any polar solvent, say a C1-4 alkanol can be used instead of water for conducting the reaction in admixture with the water-immiscible inert organic solvent, resulting in a homogeneous phase, such polar solvents, however, do not contribute in reducing the formation of impurities. Water, on the other hand, when employed in admixture with a water-immiscible inert organic solvent ensures a heterogenous biphasic system, which substantially helps minimization of the impurities.
- The addition of water helps in partial dissolution of the reactants as a result of which agitation of the reaction mass becomes easier. Absence of water in the reaction medium makes agitation of the reaction mass very difficult.
- The high selectivity of water over a C1-4 alkanol in affecting the minimization of impurities can be understood form Table-II.
-
TABLE II The effect of water and a C1-4 alkanol (methanol) in admixture with a water-immiscible inert organic solvent in the level of impurities formed in the method for preparation of ceftiofur (I) by reaction of 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III) with [2-(2-aminothiazol-4-yl)]-2-methoxyimino acetic acid-2-benzothiazolyl ester of formula (II) Impurities (%) Formed in the Present in the No. Reaction Medium reaction isolated product 1 Water + Dichloromethane 4.00 1.30 2 Methanol + Dichloromethane 11.00 4.00 - While the ratio of the water-immiscible inert organic solvent to water can vary from 90:10 of the former to the latter to 98:2.0 of the same, the best results are obtained when the ratio is between 95:5.0 to 97.5:2.5 of the water-immiscible inert organic solvent to water.
- For instance, the best results are obtained when the ratio of water-immiscible inert, organic solvent to water is 97.5:2.5.
- The dramatic effect brought about by the addition of water can be rationalised as follows:
- 7-amino-3-thiofuroylmethyl-3-cephalosporanic acid of formula (III) on addition of an organic base is converted to its alkyl ammonium salt (III2), which is soluble in the aqueous phase. The alkyl ammonium salt (III2) reacts with the compound of formula (II), which is soluble in the inert water immiscible solvent, apparently at the interface between the aqueous and organic phase thereby minimizing/eliminating side reactions by a mechanism which has not been clearly understood and facilitating higher conversion with lower impurity formation.
- Interestingly enough, synthesis of ceftiofur of formula (I) has not been achieved earlier utilising a heterogenous biphasic system.
- The reaction can be carried out a temperature ranging between low to ambient i. e. from 0° C. to 30° C., but preferably at a temperature ranging between 0° C. to 15° C.
- Although any base can be used, organic bases are preferred. Typical of such bases that can be employed include triethylamine, tri-n-butylamine, tert-butylamine, dicyclohexylanine, N-methyl morpholine, 2,3-dimethylaminopyridine, N-methyl pyrrolidinone etc.
- Among all the bases, tertiary amines are preferred which are selected from triethyl amine, tri-n-propyl amine, tri-n-butyl amine. Triethyl amine is preferred among the tertiary amines as impurity formation is minimized.
- The rise in impurity formation by using organic bases having higher number of carbon atoms may be presumably due to the increase in the hydrophobicity of the trialkyl ammonium salt (III2) with the increase in the number of carbon atoms in the trialkyl amine. This increase in hydrophobicity leads to increase in the solubility of the trialkyl ammonium salt (III2) in the hydrophobic solvent due to which the acylation takes place in the hydrophobic solvent and not at the interphase between the aqueous phase and the hydrophobic phase resulting in a rise in the level of impurities.
- The base can be employed in molar proportions of 1.0 mole to 3.0 moles per mole of compound of formula (III). Preferably the base is employed in molar proportions of 1.0 moles to 2.0 moles per mole of the compound of formula (III).
- [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester of formula (II) is employed in molar proportions of 1.0 to 2.0 moles per mole of the compound of formula (III), but preferably in a molar proportion of 1.0-1.5 moles.
- The progress of the reaction can be monitored by TLC or HPLC and typically depending upon the temperature employed the reaction is over in a period ranging from 1.0 to 3.0 hours, with the monitoring system indicating more than 95% conversion to ceftiofur (I).
- At the end of the reaction water is added, the aqueous layer is separated and further washed with a water-immiscible organic solvent selected from a chlorinated solvent such as dichloromethane, dichloroethane, chloroform or C1-6 alkyl acetate like ethyl acetate, propyl acetate, n-butyl acetate at least once.
- To the aqueous layer is added a mixture of a water-miscible solvent and a water-immiscible solvent, after separation of the organic layer.
- The water-miscible organic solvent is selected from nitriles such as acetonitrile, propionitrile, butyronitrile or ketones such as acetone, methyl ethyl ketone or polar aprotic solvents like dimethyl sulphoxide, sulpholane. The preferred water-miscible solvent is a nitrile, preferably acetonitrile.
- The water-immiscible solvent is selected from chlorinated solvents like dichloromethane, dichloroethane, chloroform or C1-6 alkyl acetates like ethyl acetate, n-butyl acetate, isopropyl acetate but preferably ethyl acetate.
- A mixture of alkyl acetate preferably ethyl acetate and nitrile preferably acetonitrile is added to the aqueous layer containing the alkyl ammonium salt of ceftiofur (I).
- The ratio of the mixture of water-miscible solvent and water-immiscible solvent is between (1:1) and (5:1) but preferably the ratio of alkyl acetate and the polar aprotic solvent is (2:1 or 3:1).
- The pH of the mixture is adjusted to 3.0±0.1 by addition of orthophosphoric acid and the mixture agitated further for complete liberating the ceftiofur (I) free acid from its corresponding salt with a organic base and taking it to the organic phase.
- A mineral acid selected from hydrochloric acid, sulphuric acid, orthophosphoric acid but preferably orthophosphoric acid is added to the biphasic mixture.
- A saturated solution of an alkali or an alkaline earth metal containing salt (15-30%) is added to the biphasic system and agitated at ambient temperature. The organic layer is separated and the aqueous layer is optionally again extracted with a mixture of water-miscible solvent and a water-immiscible solvent.
- The alkali or an alkaline earth metal containing salt is selected from sodium chloride, sodium sulphate, potassium chloride, potassium sulphate, calcium chloride, but preferably sodium chloride.
- Ceftiofur of formula (I) is isolated from the organic layer by evaporation of the organic solvent or by addition of a co-solvent.
- The co-solvent added for precipitating out ceftiofur (I) at ambient temperature from the organic layer can be a non-polar aromatic solvent like toluene, xylene or aliphatic solvent like cyclohexane, n-hexane, heptane.
- The mixture is agitated between 45-90 minutes but preferably 60 minutes for complete crystallization of pure ceftiofur (I). The pure compound (I) is filtered, washed with cyclohexane and dried at 35-40° C. The purity of ceftiofur (I) thus obtained has purity above 97% and substantially free from impurities such as the dimer compound (IV) and thiol compound (V).
- Ceftiofur acid of formula (I) thus prepared, exhibits remarkable stability under stringent temperature and humidity conditions of 40±2° C. and relative humidity of 75%±5° C. even after 3 months of storage.
- In a specific embodiment, 7-Amino-3-thiomethyl furoyl-3-cephem-4-carboxylic acid (1.0 mole) of formula (III) is added to dichloromethane and the mixture cooled between 0 and 5° C. Triethyl amine (1.8 moles) is added to the mixture followed by [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester (1.2 moles) of formula (II) is added to the mixture with agitation. Water [0.4 times volume per gram of the compound of formula (III)] is added to the reaction mixture and agitated between 1.5 to 3.0 hours for the reaction to go to completion. The reaction mixture is quenched with water and the organic layer separated. The aqueous layer containing the salt of ceftiofur (I) is extracted with dichloromethane at least twice followed by extraction with ethyl acetate at least once.
- A (2:1) mixture of ethyl acetate and acetonitrile is added to the aqueous layer and agitated at ambient temperature. The pH of the mixture is adjusted to 3.0±0.1 with orthophosphoric acid (30%) at ambient temperature. A 20% aqueous solution of sodium chloride is added to the biphasic mixture and agitated. The organic layer is separated and after optional treatment with activated carbon followed by filtration through celite bed is concentrated to isolate ceftiofur of formula (I). Alternately, cyclohexane is added to the organic layer and ceftiofur of formula (I) is allowed to precipitate completely at ambient temperature. The mixture is filtered and the wet cake washed with cyclohexane followed by drying at 35-40° C. to give ceftiofur (I) substantially free from impurities and with purity greater than 97%.
- A comparison of the present method with that of prior art methods for preparation of ceftiofur (I) is given in Table-III.
-
TABLE III Synthesis of Ceftiofur (I) by the method of the present invention vis-à-vis the methods reported in prior art. Method of U.S. Pat. Method of U.S. Pat. No. 4,767,852, No. 5,026,843, Method as described extrapolated extrapolated Method of Present in U.S. Pat. No. Method as described in for synthesis of for synthesis of No. Invention 4,464,367 U.S. Pat. No. 6,458,949 ceftiofur (I). ceftiofur (I) 1 Steps One step. Requiring Two steps. Requiring Seven steps starting One step starting One step starting required no protection of the protection and from preparation of from 7-amino-3- from 7-amino-3- for 2-amino group of [2- deprotection of the 2- 4-halo-3-oxo-2- substituted-3- substituted-3- making (2-aminothiazol-4- amino group of [2-(2- methoxyimino cephem carboxylic cephem carboxylic ceftiofur yl)]-2-synmethoxy- aminothiazol-4-yl)]-2- butyric acid. acid. acid. (I) imino acetic acid synmethoxyimino derivative. acetic acid derivative. 2. Method With [2-(2- With [2-(2- With 4-halo-3-oxo-2- With [2-(2-amino- With [2-(2-amino- for aminothiazol- aminothiazol-4-yl)-2- methoxyimino butyric thiazol-4-yl)-2- thiazol-4-yl)-2- acylation 4-yl)-2-syn- syn-methoxyimino] halide on silylated 7- syn-methoxyimino) syn-methoxyimino] of the 7- methoxyimino] acetic acid (IX) amino-3-[2-furyl acetic acid (IX) acetic acid (IX) amino acetic acid (IX) activated as 1-Hydroxy carbonylthiomethyl]-3- as its 2-mercap- as its 2-mercap- group as its 2- benzotriazole derivative cephem-4-carboxylic acid tobenzothiazole tobenzothiazole mercaptobenzothi- in presence of ester ester azole ester. dicyclohexyl carbodiimide. 3. Reaction Between Between 2.0 to 4.0 Between Between Between time 1.5 to 3.0 hours hours 2.0 to 4.0 hours. 18 to 24 hours 2.0 to 4.0 hours 4. Level of 4.0 to 5.0% 26.0 to 29.0% 7.0 to 8.0% 8.0 to 10.0% 8.0 to 10.0% impurities formed during the reaction 5. Level of 1.5 to 3.0% ≈28.0% 7.0% — — impurities gummy solid gummy solid in isolated (not isolated) (not isolated) ceftiofur (I) 6. Purity of greater than 97%. — between 90-95% — — ceftiofur (I) 7. Stability Stable for 3 months at Impurity level is quite Starts degrading in the — — of 40 ± 2° C. and relative high, therefore, stability first month at 40 ± 2° C. ceftiofur humidity 75% ± 5 is low. and relative humidity sodium 75% ± 5; purity falls prepared below specified limits in from the the first month itself. acid (I) - Ceftiofur sodium can be prepared from ceftiofur acid (I) by methods disclosed in the prior art. Ceftiofur acid (I) prepared by the present method has been converted to its sodium salt by a method disclosed in a co-pending application No. 938/MUM/2002 dated Oct. 29, 2002.
- Ceftiofur sodium prepared from ceftiofur acid (I) made by the present method has higher stability due to the lower level of impurities generated during the preparation of ceftiofur acid (I) and is also amenable to formulation as a dosage form.
- The invention can be further illustrated by the following examples, which however should not be construed to be limiting the scope of the invention.
- 7-amino-3-(2-furanylcarbonylthiomethyl)-3-cephem-4-carboxylic acid(III) (100 gms; 0.294 moles) was added to dichloromethane (1000 ml). The reaction mixture was cooled to 0° C. and triethyl amine (53.57 gms; 0.529 moles) was added at 0-5° C. in 60 minutes. [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester (II) (123.5 gms; 0.353 moles) was added and agitated for 15 minutes. Water (25.0 ml) was added to the mixture and agitated at 5-7° C. The reaction was monitored by HPLC and the mixture stirred till compound (III) was less than 1.0% on HPLC. The reaction mixture was worked up by adding water (700 ml) and stirred for 15 minutes at 10-15° C. The aqueous layer was separated and washed thrice with dichloromethane (300 ml). The aqueous layer was then again washed with ethyl acetate (300 ml). The aqueous layer was separated and a mixture of ethyl acetate (2000 ml) and acetonitrile (1000 ml) were added to the aqueous layer. The pH was adjusted to 3.0 by adding 25% orthophosphoric acid in 30 minutes at 15-20° C. A concentrated solution of sodium chloride (25%) was added to the biphasic mixture and the resulting biphasic mixture was agitated for 30 minutes. The organic layer was separated and the aqueous layer re-extracted with a (2:1) mixture of ethyl acetate and acetonitrile (750 ml). The organic layers were combined and washed with 5% brine solution. The organic layer was separated and after optional carbon treatment followed by filtration was dried on sodium sulphate. The organic layer was evaporated and a mixture of ethyl acetate (300 ml) and cyclohexane (1500 ml) was added to the residue and agitated at 20-25° C. for 60 minutes. The product (I) was filtered and washed twice with cyclohexane (200 ml). The product was dried at 35-40° C. under reduced pressure to give 100.3 gms of ceftiofur (I). % yield: 66.95; Purity: 98.5%. Total impurity: 1.50%
- 7-amino-3-(2-furanylcarbonylthiomethyl)-3-cephem-4-carboxylic acid (III) (5.0 gms; 0.0147 moles) was added to dichloromethane (50 ml). The reaction mixture was cooled to 0° C. and [2-(2-aminothiazol-4-yl)]-2-syn-methoxyimino acetic acid-2-benzothiazolyl thioester (H) (5.4 gms; 0.0154 moles) was added to the mixture with agitation. Triethyl amine (2.67 gms; 0.0264 moles) was added to the mixture followed by methanol (2.5 ml). The reaction mixture was monitored by HPLC and stirred for 3.0 hours at 5±2° C.; the reaction was not going to completion as 2.5% was remaining unreacted even after stirring further for 2.0 hours. The reaction mixture was quenched with water. The aqueous layer was washed with dichloromethane (45 ml) at least once followed by washing with ethyl acetate (45 ml). Ethyl acetate (15 m) was added to the aqueous layer and the pH was adjusted to pH 3 with 30% orthophosphoric acid. The organic layer was separated dried on sodium sulphate and evaporated between 25-30° C. under reduced pressure. A mixture of ethyl acetate (300 ml) and cyclohexane (1500 ml) was added to the residue and agitated at 20-25° C. for 60 minutes. The product (I) was filtered and washed twice with cyclohexane (200 ml). The product was dried at 35-40° C. under reduced pressure to give 4.66 gms. % yield: 64.5%; Purity: 96.1% Total impurity: 3.9%.
Claims (2)
1-18. (canceled)
19. A process for making the ceftiofur sodium of formula (XI) of high purity, stability and substantially free from impurities, comprising,
reacting ceftiofur of formula (I),
with sodium-2-ethyl hexanoate in an aqueous mixture of water miscible organic solvents and in the presence of an organic base.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/150,744 US20080207912A1 (en) | 2002-10-29 | 2008-04-30 | Method for manufacture of ceftiofur |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN937/MUM/2002 | 2002-10-29 | ||
| IN937MU2002 | 2002-10-29 | ||
| US10/532,194 US7511135B2 (en) | 2002-10-29 | 2003-10-27 | Method for manufacture of ceftiofur |
| PCT/IN2003/000345 WO2004039811A2 (en) | 2002-10-29 | 2003-10-27 | A method for manufacture of ceftiofur |
| US12/150,744 US20080207912A1 (en) | 2002-10-29 | 2008-04-30 | Method for manufacture of ceftiofur |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/532,194 Division US7511135B2 (en) | 2002-10-29 | 2003-10-27 | Method for manufacture of ceftiofur |
| PCT/IN2003/000345 Division WO2004039811A2 (en) | 2002-10-29 | 2003-10-27 | A method for manufacture of ceftiofur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20080207912A1 true US20080207912A1 (en) | 2008-08-28 |
Family
ID=32211318
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/532,194 Expired - Fee Related US7511135B2 (en) | 2002-10-29 | 2003-10-27 | Method for manufacture of ceftiofur |
| US12/150,744 Abandoned US20080207912A1 (en) | 2002-10-29 | 2008-04-30 | Method for manufacture of ceftiofur |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US10/532,194 Expired - Fee Related US7511135B2 (en) | 2002-10-29 | 2003-10-27 | Method for manufacture of ceftiofur |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7511135B2 (en) |
| EP (1) | EP1556388B1 (en) |
| JP (1) | JP2006507290A (en) |
| AT (1) | ATE373667T1 (en) |
| AU (1) | AU2003300691A1 (en) |
| CA (1) | CA2503885A1 (en) |
| DE (1) | DE60316459T2 (en) |
| ES (1) | ES2294367T3 (en) |
| NZ (1) | NZ540225A (en) |
| WO (1) | WO2004039811A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080221076A1 (en) * | 2005-10-12 | 2008-09-11 | Orchid Chemicals And Pharmaceuticals Limited | Crystalline Sodium Salt of Cephalosporin Antibiotic |
| US20110059933A1 (en) * | 2005-10-12 | 2011-03-10 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
| US20110136777A1 (en) * | 2008-08-22 | 2011-06-09 | Orchid Chemicals And Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7335767B2 (en) * | 2002-10-29 | 2008-02-26 | Lupin Limited | Method for preparation of ceftiofur and salts thereof |
| AU2003300691A1 (en) * | 2002-10-29 | 2004-05-25 | Lupin Limited | A method for manufacture of ceftiofur |
| WO2012049576A1 (en) * | 2010-10-13 | 2012-04-19 | Orchid Chemicals And Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
| CN102584855B (en) * | 2012-02-16 | 2014-06-25 | 青岛科技大学 | Improved method for preparing ceftiofur |
| CN107056816B (en) * | 2017-04-26 | 2019-11-15 | 齐鲁动物保健品有限公司 | A kind of method for crystallising of ceftiofur sodium |
| CN116003439A (en) * | 2023-01-05 | 2023-04-25 | 山东久隆信和药业有限公司 | Refining method of ceftiofur hydrochloride |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937330A (en) * | 1985-08-12 | 1990-06-26 | The Upjohn Company | Conversion of cephalosporin hydrohalide salt to alkali metal salt |
| US6388070B1 (en) * | 2001-01-05 | 2002-05-14 | Orchid Chemicals & Pharmaceuticals Ltd. | Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds |
| US20020082248A1 (en) * | 2000-11-22 | 2002-06-27 | Andreas Berger | Organic Compounds |
| US6458949B1 (en) * | 2000-08-14 | 2002-10-01 | Aurobindo Pharma Limited | Ceftiofur, its intermediate and a process for the preparation of the same |
| US6555680B1 (en) * | 2001-12-10 | 2003-04-29 | Orchid Chemicals & Pharmaceuticals Ltd. | Method for the preparation of ceftiofur sodium |
| US20040132996A1 (en) * | 2002-10-29 | 2004-07-08 | Lupin Limited | Method for preparation of ceftiofur and salts thereof |
| US6803461B2 (en) * | 2002-01-04 | 2004-10-12 | Orchid Chemicals And Pharmaceuticals Limited | Synthesis of ceftiofur intermediate |
| US20050119244A1 (en) * | 2003-12-02 | 2005-06-02 | Acs Dobfar S.P.A. | Process for preparing cephalosporins with salified intermediate |
| US20060094872A1 (en) * | 2003-08-22 | 2006-05-04 | Orchid Chemicals & Pharmaceuticals Ltd. | Process for the preparation of cephalosporin antibiotic |
| US20060135761A1 (en) * | 2002-12-26 | 2006-06-22 | Lupin Limited | Novel intermediates for synthesis of cephalosporins and process for preparation of such intermediates |
| US7345169B2 (en) * | 2003-08-22 | 2008-03-18 | Orchid Chemicals & Pharmaceuticals Ltd. | Process for the preparation of cephalosporin antibiotic |
| US20080221076A1 (en) * | 2005-10-12 | 2008-09-11 | Orchid Chemicals And Pharmaceuticals Limited | Crystalline Sodium Salt of Cephalosporin Antibiotic |
| US7511135B2 (en) * | 2002-10-29 | 2009-03-31 | Lupin Limited | Method for manufacture of ceftiofur |
-
2003
- 2003-10-27 AU AU2003300691A patent/AU2003300691A1/en not_active Abandoned
- 2003-10-27 AT AT03809833T patent/ATE373667T1/en not_active IP Right Cessation
- 2003-10-27 JP JP2004547964A patent/JP2006507290A/en active Pending
- 2003-10-27 NZ NZ540225A patent/NZ540225A/en unknown
- 2003-10-27 EP EP03809833A patent/EP1556388B1/en not_active Expired - Lifetime
- 2003-10-27 CA CA002503885A patent/CA2503885A1/en not_active Abandoned
- 2003-10-27 US US10/532,194 patent/US7511135B2/en not_active Expired - Fee Related
- 2003-10-27 ES ES03809833T patent/ES2294367T3/en not_active Expired - Lifetime
- 2003-10-27 DE DE60316459T patent/DE60316459T2/en not_active Expired - Lifetime
- 2003-10-27 WO PCT/IN2003/000345 patent/WO2004039811A2/en not_active Ceased
-
2008
- 2008-04-30 US US12/150,744 patent/US20080207912A1/en not_active Abandoned
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4937330A (en) * | 1985-08-12 | 1990-06-26 | The Upjohn Company | Conversion of cephalosporin hydrohalide salt to alkali metal salt |
| US6458949B1 (en) * | 2000-08-14 | 2002-10-01 | Aurobindo Pharma Limited | Ceftiofur, its intermediate and a process for the preparation of the same |
| US20020082248A1 (en) * | 2000-11-22 | 2002-06-27 | Andreas Berger | Organic Compounds |
| US6388070B1 (en) * | 2001-01-05 | 2002-05-14 | Orchid Chemicals & Pharmaceuticals Ltd. | Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds |
| US6555680B1 (en) * | 2001-12-10 | 2003-04-29 | Orchid Chemicals & Pharmaceuticals Ltd. | Method for the preparation of ceftiofur sodium |
| US6803461B2 (en) * | 2002-01-04 | 2004-10-12 | Orchid Chemicals And Pharmaceuticals Limited | Synthesis of ceftiofur intermediate |
| US20040132996A1 (en) * | 2002-10-29 | 2004-07-08 | Lupin Limited | Method for preparation of ceftiofur and salts thereof |
| US7335767B2 (en) * | 2002-10-29 | 2008-02-26 | Lupin Limited | Method for preparation of ceftiofur and salts thereof |
| US7511135B2 (en) * | 2002-10-29 | 2009-03-31 | Lupin Limited | Method for manufacture of ceftiofur |
| US20060135761A1 (en) * | 2002-12-26 | 2006-06-22 | Lupin Limited | Novel intermediates for synthesis of cephalosporins and process for preparation of such intermediates |
| US20060094872A1 (en) * | 2003-08-22 | 2006-05-04 | Orchid Chemicals & Pharmaceuticals Ltd. | Process for the preparation of cephalosporin antibiotic |
| US7345169B2 (en) * | 2003-08-22 | 2008-03-18 | Orchid Chemicals & Pharmaceuticals Ltd. | Process for the preparation of cephalosporin antibiotic |
| US20050119244A1 (en) * | 2003-12-02 | 2005-06-02 | Acs Dobfar S.P.A. | Process for preparing cephalosporins with salified intermediate |
| US7071329B2 (en) * | 2003-12-02 | 2006-07-04 | Acs Dobfar S.P.A. | Process for preparing cephalosporins with salified intermediate |
| US20080221076A1 (en) * | 2005-10-12 | 2008-09-11 | Orchid Chemicals And Pharmaceuticals Limited | Crystalline Sodium Salt of Cephalosporin Antibiotic |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080221076A1 (en) * | 2005-10-12 | 2008-09-11 | Orchid Chemicals And Pharmaceuticals Limited | Crystalline Sodium Salt of Cephalosporin Antibiotic |
| US20110059933A1 (en) * | 2005-10-12 | 2011-03-10 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
| US8212024B2 (en) * | 2005-10-12 | 2012-07-03 | Orchid Chemicals & Pharmaceuticals Ltd. | Crystalline sodium salt of cephalosporin antibiotic |
| US8470809B2 (en) * | 2005-10-12 | 2013-06-25 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
| US20110136777A1 (en) * | 2008-08-22 | 2011-06-09 | Orchid Chemicals And Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
| US8431562B2 (en) * | 2008-08-22 | 2013-04-30 | Orchid Chemicals & Pharmaceuticals Limited | Crystalline sodium salt of cephalosporin antibiotic |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60316459D1 (en) | 2007-10-31 |
| CA2503885A1 (en) | 2004-05-13 |
| JP2006507290A (en) | 2006-03-02 |
| DE60316459T2 (en) | 2008-06-19 |
| ES2294367T3 (en) | 2008-04-01 |
| US7511135B2 (en) | 2009-03-31 |
| EP1556388B1 (en) | 2007-09-19 |
| NZ540225A (en) | 2007-06-29 |
| EP1556388A2 (en) | 2005-07-27 |
| WO2004039811A2 (en) | 2004-05-13 |
| WO2004039811A3 (en) | 2004-08-12 |
| ATE373667T1 (en) | 2007-10-15 |
| US20060149054A1 (en) | 2006-07-06 |
| AU2003300691A1 (en) | 2004-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080207912A1 (en) | Method for manufacture of ceftiofur | |
| EP0175610A2 (en) | New cephalosporin compounds and the production thereof | |
| US20080200670A1 (en) | Method for the manufacture of ceftriaxone sodium | |
| FI63586C (en) | PROCEDURE FOR THE FRAMSTATION OF AV 7-BETA- (2-OXYIMINO-2-ARYLACETAMIDO) -3- (SULFOALKYLTETRAZOLE-5-YLTHOMETHYL) -3-CEFEM-4-CARBOXYLSYROR WITH ANTIBACTERIAL NETWORK | |
| US20050059820A1 (en) | Method for manufacture of ceftriaxone sodium | |
| JPH09132578A (en) | Cephalosporin derivative | |
| US20050020561A1 (en) | Process for the preparation of cefpodoxime acid | |
| EP0392796A3 (en) | Cephalosporin derivatives | |
| CZ195097A3 (en) | Process for preparing cephotaxim and a sodium salt thereof | |
| EP0628561B1 (en) | Process for preparing cephalosporin compounds from reactive organic acid derivatives | |
| EP1409492B1 (en) | An improved method for preparation of cefuroxime axetil | |
| US6610845B1 (en) | Thioester derivatives of thiazolyl acetic acid and their use in the preparation of cephalosporin compounds | |
| US20030199712A1 (en) | Process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds | |
| HU212782B (en) | Water-free acylating process for stereospecifical producing antibioticum cephepim-dihydrochloride-hydrate | |
| NZ234004A (en) | Crystalline, enterally absorbable salts of alpha-(2,2-dimethylpropanoyloxy)ethyl 7-(2-(2-aminothiazol-4-yl)-2-(z)-hydroxyimino-acetamido)-3- methoxymethyl-3-cephem-4-carboxylate; pharmaceutical preparation and process for preparation | |
| IE46651B1 (en) | New oxime derivatives of 3-thiadiazolyl thiomethyl-7-aminothiazolylacetamido-cephalosporanic acid,processes for preparing them and pharmaceutical compositions containing them | |
| CA1215355A (en) | Cephalosporin esters, their production and use | |
| DE69702463T2 (en) | Process for the preparation of cephalosporin derivatives and intermediates | |
| WO2005076694A2 (en) | Improved process for the production of cefotaxime sodium | |
| JPH07165765A (en) | New preparation of cephalosporin derivative | |
| US4857521A (en) | Trialkylsilyl pyridinium cephalosporin antibiotics | |
| CA1117522A (en) | Cephalosporin esters | |
| AU2002307885A1 (en) | Process for the preparation of cefpodoxime acid | |
| EP0347459A1 (en) | Cephalosporin compounds or their salts, process for their preparation, and pharmaceutical compositions | |
| JPH0513949B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |